Given its correlation with rapid tumor progression and poor prognosis in several embryonal cancers MYCN is considered an ideal therapeutic target, but many direct or indirect MYCN modulators failed to result in an efficient MYCN specific therapy51,52. The gene discussed is MYCN; the disease is embryonal neoplasm.